HAE 📈 Haemonetics - Overview

Haemonetics Corporation is a prominent player in the healthcare industry, delivering a comprehensive suite of medical products and solutions globally. The company's product portfolio encompasses a wide range of automated plasma collection systems, including the NexSys PCS and PCS2 plasmapheresis equipment, as well as related disposables and software solutions. These systems are designed to facilitate efficient plasma collection, while the accompanying software solutions, such as the NexLynk DMS donor management system and Donor360 app, enable plasma customers to effectively manage their donors, operations, and supply chain. Additionally, the company provides integrated information technology platforms that cater to the specific needs of plasma customers.

The company's product offerings also extend to automated blood component and manual whole blood collection systems, including the MCS brand apheresis equipment, which is used to collect specific blood components from donors. Furthermore, Haemonetics provides disposable whole blood collection and component storage sets, as well as the SafeTrace Tx blood bank information system and BloodTrack blood management software. The BloodTrack software is a suite of blood management and bedside transfusion solutions that combines software with hardware components, providing an extension of the hospital's blood bank information system. This comprehensive suite of products enables healthcare professionals to streamline their blood management processes, ensuring efficient and effective patient care.

Haemonetics' hospital products include the TEG and HAS hemostasis analyzer systems, which provide a comprehensive assessment of a patient's overall hemostasis. The TEG Manager software connects various TEG analyzers throughout the hospital, providing clinicians with remote access to active and historical test results that inform treatment decisions. The company also offers the Cell Saver Elite +, an autologous blood recovery system used in various surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. Moreover, Haemonetics' VASCADE products, comprising VASCADE and VASCADE MVP, leverage the natural clot-inducing properties of collagen to provide a catheter-based delivery system.

Haemonetics sells its products through a direct sales force, as well as independent distributors and sales representatives. With a history dating back to 1971, the company is headquartered in Boston, Massachusetts, and has established itself as a leading provider of healthcare solutions. As a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol HAE, Haemonetics Corporation is committed to delivering innovative products and solutions that meet the evolving needs of the healthcare industry. The company's website, https://www.haemonetics.com, provides further information on its products and services, while its ISIN code, US4050241003, and GICS Sub Industry classification as Health Care Supplies, provide additional context for investors and industry stakeholders.